<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213148</url>
  </required_header>
  <id_info>
    <org_study_id>25550</org_study_id>
    <nct_id>NCT00213148</nct_id>
  </id_info>
  <brief_title>Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction</brief_title>
  <official_title>A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and compare the safety and efficacy of various
      doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating
      follicular growth and ovulation in infertile women with ovulatory dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2005</start_date>
  <completion_date type="Actual">December 12, 2007</completion_date>
  <primary_completion_date type="Actual">December 12, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation Rate in Cycle 1</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron [P4] level greater than or equal to [&gt;=] 10 nanogram per milliliter [ng/mL] and/or pregnancy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Pregnancy in Cycle 1</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Clomiphene Citrate 50 Milligram (mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomiphene Citrate 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole 1 mg</intervention_name>
    <description>Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).</description>
    <arm_group_label>Anastrozole 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole 5 mg</intervention_name>
    <description>Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).</description>
    <arm_group_label>Anastrozole 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole 10 mg</intervention_name>
    <description>Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).</description>
    <arm_group_label>Anastrozole 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate 50 mg</intervention_name>
    <description>Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).</description>
    <arm_group_label>Clomiphene Citrate 50 Milligram (mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate 100 mg</intervention_name>
    <description>Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).</description>
    <arm_group_label>Clomiphene Citrate 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-40 years

          -  Ovulatory dysfunction characterized by irregular and/or extended cycles

          -  Non-smoker

        Exclusion Criteria:

          -  No previous gonadotropin treatment

          -  No more than 6 previous clomiphene treatment cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local US Medical Information</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <zip>02370</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>September 21, 2017</results_first_submitted>
  <results_first_submitted_qc>September 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clomiphene Citrate 50 Milligram (mg)</title>
          <description>Subjects were administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Subjects in this arm were re-randomized at the start of Cycle 2 and Cycle 3 and either continued receiving Clomiphene Citrate 50 mg or moved to Clomiphene Citrate 100 mg arm.</description>
        </group>
        <group group_id="P2">
          <title>Clomiphene Citrate 100 mg</title>
          <description>Subjects from Clomiphene Citrate 50 mg arm who were re-randomized at the start of Cycle 2 and Cycle 3 and were administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month) were presented.</description>
        </group>
        <group group_id="P3">
          <title>Anastrozole 1 mg</title>
          <description>Subjects were administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Subjects in this arm were re-randomized at the start of Cycle 2 and Cycle 3 and either continued receiving Anastrozole 1 mg or moved to Anastrozole 10 mg arm.</description>
        </group>
        <group group_id="P4">
          <title>Anastrozole 5 mg</title>
          <description>Subjects were administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Subjects in this arm were re-randomized at the start of Cycle 2 and Cycle 3 and either continued receiving Anastrozole 5 mg or moved to Anastrozole 10 mg arm.</description>
        </group>
        <group group_id="P5">
          <title>Anastrozole 10 mg</title>
          <description>Subjects were administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Some of the subjects from Anastrozole 1 mg and 5 mg arms were re-randomized at the start of Cycle 2 and Cycle 3 to Anastrozole 10 mg arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cycle 1 (1 Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy Unrelated to Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Resolving Cyst &gt; 25mm</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Before Start of Cycle 2</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cycle 2 (1 Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy Unrelated to Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Resolving Cyst &gt; 25mm</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Before Start of Cycle 3</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cycle 3 (1 Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clomiphene Citrate 50 mg</title>
          <description>Subjects were administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Subjects in this arm were re-randomized at the start of Cycle 2 and Cycle 3 and either continued receiving Clomiphene Citrate 50 mg or moved to Clomiphene Citrate 100 mg arm.</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole 1 mg</title>
          <description>Subjects were administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Subjects in this arm were re-randomized at the start of Cycle 2 and Cycle 3 and either continued receiving Anastrozole 1 mg or moved to Anastrozole 10 mg arm.</description>
        </group>
        <group group_id="B3">
          <title>Anastrozole 5 mg</title>
          <description>Subjects were administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Subjects in this arm were re-randomized at the start of Cycle 2 and Cycle 3 and either continued receiving Anastrozole 5 mg or moved to Anastrozole 10 mg arm.</description>
        </group>
        <group group_id="B4">
          <title>Anastrozole 10 mg</title>
          <description>Subjects were administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month). Some of the subjects from Anastrozole 1 mg and 5 mg arms were re-randomized at the start of Cycle 2 and Cycle 3 to Anastrozole 10 mg arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="76"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="3.9"/>
                    <measurement group_id="B2" value="28.8" spread="3.9"/>
                    <measurement group_id="B3" value="29.6" spread="3.9"/>
                    <measurement group_id="B4" value="29.3" spread="3.4"/>
                    <measurement group_id="B5" value="29.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ovulation Rate in Cycle 1</title>
        <description>Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron [P4] level greater than or equal to [&gt;=] 10 nanogram per milliliter [ng/mL] and/or pregnancy).</description>
        <time_frame>Up to 1 month</time_frame>
        <population>All Treated population included all treated subjects who received at least one tablet of study drug (clomiphene citrate or anastrozole).</population>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene Citrate 50 mg</title>
            <description>Subjects were administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1.</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole 1 mg</title>
            <description>Subjects were administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Anastrozole 5 mg</title>
            <description>Subjects were administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Anastrozole 10 mg</title>
            <description>Subjects were administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Rate in Cycle 1</title>
          <description>Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron [P4] level greater than or equal to [&gt;=] 10 nanogram per milliliter [ng/mL] and/or pregnancy).</description>
          <population>All Treated population included all treated subjects who received at least one tablet of study drug (clomiphene citrate or anastrozole).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="36.8"/>
                    <measurement group_id="O4" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Pregnancy in Cycle 1</title>
        <description>Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.</description>
        <time_frame>Up to 1 month</time_frame>
        <population>All Treated population included all treated subjects who received at least one tablet of study drug (CC or anastrozole).</population>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene Citrate 50 mg</title>
            <description>Subjects were administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1.</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole 1 mg</title>
            <description>Subjects were administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Anastrozole 5 mg</title>
            <description>Subjects were administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Anastrozole 10 mg</title>
            <description>Subjects were administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Pregnancy in Cycle 1</title>
          <description>Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.</description>
          <population>All Treated population included all treated subjects who received at least one tablet of study drug (CC or anastrozole).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clomiphene Citrate 50 mg (Cycle 1)</title>
          <description>Subjects administered orally with 50 mg of clomiphene citrate once daily for 5 days in cycle 1 were presented.</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole 1 mg (Cycle 1)</title>
          <description>Subjects administered orally with 1 mg of Anastrozole once daily for 5 days in cycle 1 were presented.</description>
        </group>
        <group group_id="E3">
          <title>Anastrozole 5 mg (Cycle 1)</title>
          <description>Subjects administered orally with 5 mg of Anastrozole once daily for 5 days in cycle 1 were presented.</description>
        </group>
        <group group_id="E4">
          <title>Anastrozole 10 mg (Cycle 1)</title>
          <description>Subjects administered orally with 10 mg of Anastrozole once daily for 5 days in cycle 1 were presented.</description>
        </group>
        <group group_id="E5">
          <title>Clomiphene Citrate 50 mg (Cycle 2)</title>
          <description>Subjects administered orally with 50 mg of clomiphene citrate once daily for 5 days in cycle 2 were presented.</description>
        </group>
        <group group_id="E6">
          <title>Clomiphene Citrate 100 mg (Cycle 2)</title>
          <description>Subjects administered orally with 100 mg of clomiphene citrate once daily for 5 days in cycle 2 were presented.</description>
        </group>
        <group group_id="E7">
          <title>Anastrozole 1 mg (Cycle 2)</title>
          <description>Subjects administered orally with 1 mg of Anastrozole once daily for 5 days in cycle 2 were presented.</description>
        </group>
        <group group_id="E8">
          <title>Anastrozole 5 mg (Cycle 2)</title>
          <description>Subjects administered orally with 5 mg of Anastrozole once daily for 5 days in cycle 2 were presented.</description>
        </group>
        <group group_id="E9">
          <title>Anastrozole 10 mg (Cycle 2)</title>
          <description>Subjects administered orally with 10 mg of Anastrozole once daily for 5 days in cycle 2 were presented.</description>
        </group>
        <group group_id="E10">
          <title>Clomiphene Citrate 50 mg (Cycle 3)</title>
          <description>Subjects administered orally with 50 mg of clomiphene citrate once daily for 5 days in cycle 3 were presented.</description>
        </group>
        <group group_id="E11">
          <title>Clomiphene Citrate 100 mg (Cycle 3)</title>
          <description>Subjects administered orally with 100 mg of clomiphene citrate once daily for 5 days in cycle 3 were presented.</description>
        </group>
        <group group_id="E12">
          <title>Anastrozole 1 mg (Cycle 3)</title>
          <description>Subjects administered orally with 1 mg of Anastrozole once daily for 5 days in cycle 3 were presented.</description>
        </group>
        <group group_id="E13">
          <title>Anastrozole 5 mg (Cycle 3)</title>
          <description>Subjects administered orally with 5 mg of Anastrozole once daily for 5 days in cycle 3 were presented.</description>
        </group>
        <group group_id="E14">
          <title>Anastrozole 10 mg (Cycle 3)</title>
          <description>Subjects were administered orally with 10 mg of Anastrozole once daily for 5 days in cycle 3 were presented.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Healthcare, a business of Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

